Inventaire - your friends and communities are your best library

Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate

author

Sonata Jarmalaite

Feliksas Jankevicius

Juozas Rimantas Lazutka

1960 -

Arnas Bakavicius

published in: Journal of Urology

date of publication: 2020-02-18

main subject: whole blood

Cites articles 28

Date

Title

Authors

2018-06-01

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer

Sarah Q To, Heidi C Fettke, Kate L Mahon, Lisa G Horvath
2018-04-16

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

Karim Fizazi, Philip W. Kantoff, Srinivasan Yegnasubramanian
2018-07-10

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

Heini Kallio, Matti Nykter, William B Isaacs
2018-09-12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Frank Bray
2018-12-06

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

Jacques Ferlay, Donald Maxwell Parkin, Ariana Znaor, Frank Bray
2017-04-06

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Kenneth J. Pienta
2017-08-14

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Andreas Bietenbeck, Silvia Thoene, Christof Winter
2017-12-16

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting

Ralf Kittler, Luke A. Selth, Wayne D Tilley
2016-01-28

Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer

Masayoshi Zaitsu
2016-05-01

Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer.
2016-07-17

AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate

Bernhard Eigl, Anthony M Joshua
2016-07-20

Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer

David T Ting
2016-07-20

A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer

Yan Dong
2016-08-03

Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer

Philip W. Kantoff, Mari Nakabayashi, Christopher Sweeney, Wanling Xie, Gwo-Shu Mary Lee, Oliver Sartor
2016-12-12

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer

Howard I Scher
2016-12-23

Improved survival for patients with de novo metastatic prostate cancer in the last 20 years

Inga Jóna Ingimarsdóttir
2016-12-09

Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor

Edward M Schaeffer
2014-06-26

Prognostic value of RASSF1 promoter methylation in prostate cancer.

Kristina Daniunaite, Arvydas Laurinavicius, Sonata Jarmalaite, Feliksas Jankevicius, Juozas Rimantas Lazutka
2014-09-11

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Tamara L Lotan, William B Isaacs, Angelo M De Marzo
2013-07-15

Mechanisms of the androgen receptor splicing in prostate cancer cells
2013-07-26

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival

Hans Lilja, Nikolaus Schultz
2013-11-01

A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer
2012-04-16

Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.

Arvydas Laurinavicius, Sonata Jarmalaite, Feliksas Jankevicius, Juozas Rimantas Lazutka
2011-05-01

Abiraterone and increased survival in metastatic prostate cancer

Susan Ellard, Fred Saad
2010-07-19

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

Robert L Vessella
2009-01-01

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

Alan W Partin, William B Isaacs, Robert L Vessella
2009-03-15

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Joanne Edwards, Jonathan Melamed
2008-07-01

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

Robert L Vessella

Article - wd:Q89754603

Welcome to Inventaire

the library of your friends and communities

learn more